Navigation Links
ATS Medical Announces Participation in the Joint Meeting of the Society for Heart Valve Disease and Heart Valve Society of America
Date:6/25/2009

MINNEAPOLIS, June 25 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming joint meeting of the Society for Heart Valve Disease and Heart Valve Society of America, which is being held in Berlin on June 27-30, 2009. This biennial meeting is a significant gathering of cardiovascular surgeons from around the world and provides an excellent venue for the Company to exhibit its growing portfolio of clinically relevant products designed to meet the needs of cardiac surgeons.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Noteworthy for ATS Medical are several presentations focusing on the ATS Open Pivot(R) Mechanical Heart Valve and the ATS 3f(R) Aortic Bioprosthesis.

  • "Five Year Hemodynamic Performance of ATS 3f Aortic Bioprosthesis Assessed By Valve Energy Loss and Pressure Gradient," Xu Yu Jin, M.D., Oxford Heart Centre, Oxford, UK, on Sunday, June 28, 2009.
  • "The Click Within - Impact of Prosthesis Sound of Composite Grafts on Quality of Life," Mario Stalder, M.D., University Hospital Berne, Berne, Switzerland, on Monday, June 29, 2009.
  • "Clinical Experience with the ATS 3f Stentless Aortic Bioprosthesis - Five Years Follow Up," Joerg Linneweber, M.D., Klinik fur kardiovaskulare Chirurgie Charite-Universitatsmedizin Berlin, Berlin, Germany, on Monday, June 29, 2009.
  • "Fifteen Years Single Centre Experience with the ATS Bi-leaflet Valve," Professor Guido Van Nooten, University Hospital Ghent, Ghent, Belgium, on Tuesday, June 30, 2009.

Highlighting the ATS exhibition will be the ATS 3f(R) Aortic Bioprosthesis which is designed to replace the patient's diseased valve. The ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve with its tubular design that restores continuity between the annulus and the sinotubular junction. By restoring this continuity, the ATS 3f Aortic Bioprosthesis is the only aortic valve that preserves the sinuses and restores native valve stress distribution and physiologic blood flow. The ATS 3f Aortic Bioprosthesis design provides surgeons and patients with a potentially more durable solution to aortic valve replacement.

The mechanical heart valve segment will feature the flagship ATS Open Pivot(R) Heart Valve and its newest advancement, the ATS Open Pivot(R) AP360(TM) with enhanced surgical implant characteristics. The family of ATS mechanical heart valves features a unique open pivot design that results in exceptional hemodynamic performance and a low risk profile.

The ATS Simulus(R) Annuloplasty product line, designed for the heart valve repair market, will be showcased with special focus on the new ATS Simulus Semi-Rigid Annuloplasty Ring.

Exemplifying ATS's broad product offering is the ATS CryoMaze(R) Surgical Ablation System which is used to treat patients with cardiac arrhythmias. The ATS CryoMaze System provides results comparable to the gold standard cut-and-sew Cox Maze III procedure and is being used by a growing number of surgeons as their ablation technology of choice.

Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... York, New York (PRWEB) , ... April 28, ... ... high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin ... cream provides the hydrating benefits of a moisturizer with the power of an ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology: